Daniel Le Grange1, James Lock2, W Stewart Agras2, Susan W Bryson2, Booil Jo2. 1. University of California, San Francisco and The University of Chicago, IL (Emeritus). Electronic address: daniel.legrange@ucsf.edu. 2. Stanford University School of Medicine, Stanford, CA.
Abstract
OBJECTIVE: There is a paucity of randomized clinical trials (RCTs) for adolescents with bulimia nervosa (BN). Prior studies suggest cognitive-behavioral therapy adapted for adolescents (CBT-A) and family-based treatment for adolescent bulimia nervosa (FBT-BN) could be effective for this patient population. The objective of this study was to compare the relative efficacy of these 2 specific therapies, FBT-BN and CBT-A. In addition, a smaller participant group was randomized to a nonspecific treatment (supportive psychotherapy [SPT]), whose data were to be used if there were no differences between FBT-BN and CBT-A at end of treatment. METHOD: This 2-site (Chicago and Stanford) randomized controlled trial included 130 participants (aged 12-18 years) meeting DSM-IV criteria for BN or partial BN (binge eating and purging once or more per week for 6 months). Outcomes were assessed at baseline, end of treatment, and 6 and 12 months posttreatment. Treatments involved 18 outpatient sessions over 6 months. The primary outcome was defined as abstinence from binge eating and purging for 4 weeks before assessment, using the Eating Disorder Examination. RESULTS: Participants in FBT-BN achieved higher abstinence rates than in CBT-A at end of treatment (39% versus 20%; p = .040, number needed to treat [NNT] = 5) and at 6-month follow-up (44% versus 25%; p = .030, NNT = 5). Abstinence rates between these 2 groups did not differ statistically at 12-month follow-up (49% versus 32%; p = .130, NNT = 6). CONCLUSION: In this study, FBT-BN was more effective in promoting abstinence from binge eating and purging than CBT-A in adolescent BN at end of treatment and 6-month follow-up. By 12-month follow-up, there were no statistically significant differences between the 2 treatments. CLINICAL TRIAL REGISTRATION INFORMATION: Study of Treatment for Adolescents With Bulimia Nervosa; http://clinicaltrials.gov/; NCT00879151.
RCT Entities:
OBJECTIVE: There is a paucity of randomized clinical trials (RCTs) for adolescents with bulimia nervosa (BN). Prior studies suggest cognitive-behavioral therapy adapted for adolescents (CBT-A) and family-based treatment for adolescent bulimia nervosa (FBT-BN) could be effective for this patient population. The objective of this study was to compare the relative efficacy of these 2 specific therapies, FBT-BN and CBT-A. In addition, a smaller participant group was randomized to a nonspecific treatment (supportive psychotherapy [SPT]), whose data were to be used if there were no differences between FBT-BN and CBT-A at end of treatment. METHOD: This 2-site (Chicago and Stanford) randomized controlled trial included 130 participants (aged 12-18 years) meeting DSM-IV criteria for BN or partial BN (binge eating and purging once or more per week for 6 months). Outcomes were assessed at baseline, end of treatment, and 6 and 12 months posttreatment. Treatments involved 18 outpatient sessions over 6 months. The primary outcome was defined as abstinence from binge eating and purging for 4 weeks before assessment, using the Eating Disorder Examination. RESULTS:Participants in FBT-BN achieved higher abstinence rates than in CBT-A at end of treatment (39% versus 20%; p = .040, number needed to treat [NNT] = 5) and at 6-month follow-up (44% versus 25%; p = .030, NNT = 5). Abstinence rates between these 2 groups did not differ statistically at 12-month follow-up (49% versus 32%; p = .130, NNT = 6). CONCLUSION: In this study, FBT-BN was more effective in promoting abstinence from binge eating and purging than CBT-A in adolescent BN at end of treatment and 6-month follow-up. By 12-month follow-up, there were no statistically significant differences between the 2 treatments. CLINICAL TRIAL REGISTRATION INFORMATION: Study of Treatment for Adolescents With Bulimia Nervosa; http://clinicaltrials.gov/; NCT00879151.
Authors: W Stewart Agras; James Lock; Harry Brandt; Susan W Bryson; Elizabeth Dodge; Katherine A Halmi; Booil Jo; Craig Johnson; Walter Kaye; Denise Wilfley; Blake Woodside Journal: JAMA Psychiatry Date: 2014-11 Impact factor: 21.596
Authors: Scott J Crow; Sonja A Swanson; Daniel le Grange; Emily H Feig; Kathleen R Merikangas Journal: Compr Psychiatry Date: 2014-06-07 Impact factor: 3.735
Authors: Christopher G Fairburn; Zafra Cooper; Helen A Doll; Marianne E O'Connor; Kristin Bohn; Deborah M Hawker; Jackie A Wales; Robert L Palmer Journal: Am J Psychiatry Date: 2008-12-15 Impact factor: 18.112
Authors: James E Mitchell; Stewart Agras; Scott Crow; Katherine Halmi; Christopher G Fairburn; Susan Bryson; Helena Kraemer Journal: Br J Psychiatry Date: 2011-03-17 Impact factor: 9.319
Authors: Stig Poulsen; Susanne Lunn; Sarah I F Daniel; Sofie Folke; Birgit Bork Mathiesen; Hannah Katznelson; Christopher G Fairburn Journal: Am J Psychiatry Date: 2014-01 Impact factor: 18.112
Authors: Sasha Gorrell; Kathryn Kinasz; Lisa Hail; Lindsey Bruett; Sarah Forsberg; James Lock; Daniel Le Grange Journal: Eur Eat Disord Rev Date: 2019-02-07
Authors: Colleen M McGovern; Lisa K Militello; Kimberly J Arcoleo; Bernadette M Melnyk Journal: J Pediatr Health Care Date: 2018-06-22 Impact factor: 1.812
Authors: Sasha Gorrell; Lisa Hail; Kathryn Kinasz; Lindsey Bruett; Sarah Forsberg; Kevin Delucchi; James Lock; Daniel Le Grange Journal: Int J Eat Disord Date: 2019-01-30 Impact factor: 4.861